■这项研究基于FDA不良事件报告系统(FAERS)数据库进行了药物警戒分析,以比较吸入或鼻用倍氯米松的感染风险,氟替卡松,布地奈德,环索奈德,莫米松,曲安奈德.
■我们使用比例失衡分析来评估ICS/INC与感染事件之间的相关性。数据是从2015年4月至2023年9月的FAERS数据库中提取的。进一步分析其临床特点,感染部位,以及ICS和INCs感染不良事件(AEs)的病原菌。我们使用气泡图来显示它们的前5个感染不良事件。
■我们分析了21,837例与ICS和INCs相关的感染不良事件报告,平均年龄为62.12岁。其中,61.14%的感染报告与女性有关。据报道,氟替卡松感染的三分之一发生在下呼吸道,布地奈德,Ciclesonidec,和莫米松;曲安奈德报告的感染中有40%以上是眼部感染;倍氯米松引起的口腔感染率为7.39%。倍氯米松引起的真菌和病毒感染的报告率分别为21.15%和19.2%,分别。布地奈德和西索奈德引起的分枝杆菌感染分别占3.29%和2.03%,分别。气泡图显示ICS组有更多的真菌感染,口腔感染,肺炎,支气管炎,等。INCs组有更多的眼部症状,鼻炎,鼻窦炎,鼻咽炎,等。
■使用ICS和INCs的女性更容易发生感染事件。与布地奈德相比,氟替卡松似乎有较高的肺炎和口腔念珠菌病的风险。莫米松可能导致更多的上呼吸道感染。倍氯米松的口腔感染风险较高。倍氯米松会导致更多的真菌和病毒感染,而环索奈德和布地奈德更容易感染分枝杆菌。
UNASSIGNED: This study conducted a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database to compare the infection risk of inhaled or nasal Beclomethasone, Fluticasone, Budesonide, Ciclesonide, Mometasone, and Triamcinolone Acetonide.
UNASSIGNED: We used proportional imbalance analysis to evaluate the correlation between ICS /INCs and infection events. The data was extracted from the FAERS database from April 2015 to September 2023. Further analysis was conducted on the clinical characteristics, site of infection, and pathogenic bacteria of ICS and INCs infection adverse events (AEs). We used bubble charts to display their top 5 infection adverse events.
UNASSIGNED: We analyzed 21,837 reports of infection AEs related to ICS and INCs, with an average age of 62.12 years. Among them, 61.14% of infection reports were related to females. One-third of infections reported to occur in the lower respiratory tract with Fluticasone, Budesonide, Ciclesonidec, and Mometasone; over 40% of infections reported by Triamcinolone Acetonide were eye infections; the rate of oral infections caused by Beclomethasone were 7.39%. The reported rates of fungal and viral infections caused by beclomethasone were 21.15% and 19.2%, respectively. The mycobacterial infections caused by Budesonide and Ciclesonidec account for 3.29% and 2.03%, respectively. Bubble plots showed that the ICS group had more fungal infections, oral infections, pneumonia, tracheitis, etc. The INCs group had more eye symptoms, rhinitis, sinusitis, nasopharyngitis, etc.
UNASSIGNED: Women who use ICS and INCs are more prone to infection events. Compared to Budesonide, Fluticasone seemed to have a higher risk of pneumonia and oral candidiasis. Mometasone might lead to more upper respiratory tract infections. The risk of oral infection was higher with Beclomethasone. Beclomethasone causes more fungal and viral infections, while Ciclesonide and Budesonide are more susceptible to mycobacterial infections.